Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate

A technology for clopidogrel hydrogen sulfate and clopidogrel base, which is applied in the field of preparing polymorphs of clopidogrel hydrogen sulfate and can solve problems such as not recommending diethyl ether solvent and the like

Inactive Publication Date: 2011-04-13
IND SWIFT LAB
View PDF15 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] Likewise, most previous literature methods for the preparation of amorphous clopidogrel bisulfate involved diethyl ether as a solvent, which is generally not recommended on an industrial scale.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate
  • Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate
  • Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0068] Step-I: Preparation of (+) Clopidogrel Camphorsulfonate

[0069] Dimethylformamide (4.80 L) was cooled to 15-20°C, and triethylamine (1.26 g) and thieno[3,2-c]pyridine hydrochloride (1.0 kg) were added with stirring. Methyl α-bromo-(2-chlorophenyl)acetate (1.65 kg) was slowly added to the reaction mixture at 15-20°C and stirring was continued for 30 minutes. Then water (4.01) and dichloromethane (4.01) were added. After the layers were separated, dichloromethane was distilled off under reduced pressure to obtain the residue, namely ± clopidogrel free base (1.83 kg). The obtained racemic mixture of clopidogrel was taken up in acetone and 1(-)camphorsulfonic acid (1.21 kg) was added. The reaction was refluxed for 4 hours and placed at 40-45°C for 16 hours. The obtained clopidogrel camphorsulfonate was purified by reflux with 21 times volume of acetone and then cooled to 20-25°C. The crystalline product was filtered, washed with acetone and dried to obtain the title co...

example 2

[0073] Preparation of Clopidogrel Bisulfate Form I

[0074] Clopidogrel base (28 g) was dissolved in methyl isobutyl ketone (345 ml) at room temperature. Chloroform (4.5 ml) and clopidogrel Form I seeds (5.6 g) were added to the above solution, and the reaction mixture was cooled to -10 to -5°C. A cooled solution of sulfuric acid (7.2 g) in methyl isobutyl ketone (173 ml) was added dropwise to the reaction mixture at a temperature lower than 0° C. and under the protection of an inert gas. The reaction mixture was kept at the same temperature and stirred continuously for 3 hours. The temperature of the reaction mixture was then slowly increased to 15-17°C and stirring was continued for 10 hours. The product was filtered and the filter residue was washed with methyl isobutyl ketone and dried to obtain the title compound. figure 1 The shown X-ray powder diffraction pattern shows that the obtained substance is crystalline form I of clopidogrel hydrogen sulfate.

example 3

[0076] Preparation of Clopidogrel Bisulfate Form I

[0077] Clopidogrel base (28 g) was dissolved in methyl isobutyl ketone (345 ml) at room temperature. To the above solution was added carbon tetrachloride (4.5 ml) and clopidogrel Form I seeds (5.6 g). The reaction mixture was then cooled to -10 to -5°C. To the reaction mixture was added dropwise a cooled solution of sulfuric acid (7.2 g) in methyl isobutyl ketone (173 ml) at -10 to -5°C. The reaction mixture was kept at the same temperature and stirred continuously for 3 hours. The temperature of the reaction mixture was then slowly increased to 16-18°C and stirring was continued for 10 hours. The product was filtered and the filter residue was washed with methyl isobutyl ketone and dried to obtain the title compound.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl (+)-(S)-a-(o-chlorophenyl)-6,7-dihydrotliieno [3,2-c] pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.

Description

technical field [0001] The present invention relates to a kind of novel method for preparing clopidogrel bisulfate polymorph, and the present invention relates in particular to methyl (+)-(S)-alpha-(o-chlorophenyl)-6 shown in molecular formula I , polymorph I and amorphous form of 7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester hydrogensulfate. [0002] [0003] Molecular formula I Background of the invention [0004] The chemical formula of clopidogrel is methyl(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester , and its molecular structure is as follows: [0005] [0006] Clopidogrel is a well-known blood platelet aggregation inhibitor and active ingredient of antithrombotic drugs. The platelet inhibitory activity of clopidogrel makes it an effective drug for reducing ischemic stroke and heart attack caused by vascular diseases such as atherosclerosis. By inhibiting the aggregation of platelets, clopidogrel re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/425
CPCC07D495/04A61P7/02A61P9/10A61K31/425
Inventor R·萨克纳N·K·沃玛C·V·斯里尼瓦桑L·瓦德瓦
Owner IND SWIFT LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products